A 2024 narrative review finds that cannabidiol (CBD) interacts with multiple receptor systems present in oral tissues, providing a scientifically credible rationale for investigating its use in periodontal disease, oral cancer, and other dental conditions. However, the evidence reviewed is overwhelmingly preclinical, and no clinical trials in oral disease patients are cited to support any specific treatment recommendation.

Oral diseases, from periodontal inflammation to oral squamous cell carcinoma, affect billions of people worldwide, and existing treatments carry significant limitations in terms of efficacy, side effects, and patient compliance. Cannabidiol has generated enormous public and commercial interest as a potential therapeutic agent, and the oral cavity is uniquely accessible for topical and transmucosal drug delivery. With patients increasingly asking clinicians about CBD for dental pain and gum health, any published synthesis that appears to validate these uses will be rapidly cited in consumer and practitioner communities, making it essential to understand what the evidence actually supports.

This 2024 narrative review, published in Biomedicine & Pharmacotherapy by researchers at Lanzhou University, synthesizes the existing literature on cannabidiol’s pharmacological mechanisms as they relate to five categories of oral disease: periodontal disease, pulp disease, oral mucosal disorders, oral cancer, and temporomandibular joint (TMJ) disorders. The authors trace CBD’s interactions through a detailed receptor map that includes CB1, CB2, TRPV1 through TRPV4, TRPA1, TRPM8, PPARy, and 5-HT1A receptors, noting that many of these targets are expressed in oral tissues such as the periodontium, dental pulp, and oral mucosa. The mechanistic framework is internally coherent and draws on established cannabinoid pharmacology to propose anti-inflammatory, analgesic, antibacterial, antioxidant, and anti-proliferative effects potentially relevant to oral pathology.

The key findings include CBD’s reported inhibition of Porphyromonas gingivalis and methicillin-resistant Staphylococcus aureus, suppression of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) through CB2 activation, and modulation of the PI3K/AKT/mTOR pathway relevant to cancer biology. However, the supporting evidence is overwhelmingly preclinical, derived from cell culture and animal models rather than human trials. The review does not report a systematic search strategy, inclusion criteria, or quality appraisal of cited studies, and it does not present clinical trial data for any oral disease indication. The authors acknowledge that clinical validation is needed, but the review’s structure may lead readers to overestimate the readiness of CBD for dental applications. Future randomized controlled trials specific to oral disease populations are essential before any clinical recommendations can be made.

This review does something genuinely useful: it collects scattered mechanistic evidence and receptor-level data into a single, organized framework for the dental research community. The biological logic is sound. Cannabinoid receptors are in fact expressed in oral tissues, and CBD’s anti-inflammatory and analgesic properties are well-documented in other contexts. What the review does not do, and what I wish it were more explicit about, is acknowledge the enormous distance between “this receptor exists in gum tissue” and “this compound treats gum disease in patients.” That gap has swallowed many promising candidates before CBD, and it will require rigorous human trials to bridge.

In practice, I see patients who are already using CBD products for dental pain, TMJ discomfort, and inflammatory gum conditions. I do not discourage them from trying topical CBD alongside standard dental care, but I am transparent that we lack clinical evidence to predict outcomes, appropriate dosing, or long-term safety in the oral cavity. When patients ask whether CBD can replace conventional periodontal treatment, the answer is clearly no, and I explain that the science simply has not caught up with the enthusiasm.

For clinicians following the cannabinoid research landscape, this review sits squarely in the early hypothesis-generating phase. It maps where the targets are and proposes why CBD might work, but it does not test whether it does. This is a familiar stage in cannabinoid medicine: the preclinical rationale for CBD in epilepsy was similarly compelling years before the Epidiolex trials demonstrated clinical efficacy, and that journey required multiple rigorous randomized controlled trials before FDA approval. For oral diseases, we are still in the opening chapter of that story, and the review should be interpreted as a research agenda rather than a clinical guideline.

From a pharmacological and safety standpoint, clinicians should be aware that CBD has known drug interactions through CYP3A4 and CYP2C19 inhibition, which could affect metabolism of commonly prescribed dental medications including some antibiotics, anxiolytics, and analgesics used in perioperative dental care. The oral mucosal route of administration, while offering theoretical advantages for local delivery, also raises questions about local tissue effects with chronic use that have not been studied. Until controlled trials establish safety, efficacy, and dosing parameters for specific oral conditions, the most responsible clinical recommendation is to maintain evidence-based dental care as the standard while remaining open to CBD as an adjunctive option that patients may be using independently.

This is a narrative review, which occupies a relatively low position in the evidence hierarchy compared to systematic reviews, meta-analyses, and randomized controlled trials. Narrative reviews synthesize existing literature based on the authors’ selection of sources without a predefined, reproducible search protocol or formal quality appraisal of included studies. While valuable for framing research questions and generating hypotheses, the single most important constraint on inference is that a narrative review cannot establish clinical efficacy, and its conclusions are only as balanced as the literature the authors chose to include.

The mechanistic claims in this review are broadly consistent with the established cannabinoid pharmacology literature, including foundational work by Mechoulam and Parker characterizing endocannabinoid receptor systems. CBD’s anti-inflammatory activity through CB2 and its analgesic effects through TRPV1 are well-documented in non-oral contexts. However, the trajectory from preclinical promise to clinical reality in cannabinoid medicine has historically been long and uncertain. The Devinsky et al. (2017) Epidiolex trials in epilepsy illustrate that even when preclinical rationale is strong, years of rigorous randomized clinical testing are required before clinical adoption is justified. No comparable clinical trial program exists for CBD in oral diseases, placing the field substantially behind other cannabinoid therapeutic areas.

The most likely and consequential misreading of this review is the conclusion that CBD has been shown to treat periodontal disease, oral cancer, or TMJ disorders. It has not. The evidence presented is mechanistic and preclinical, meaning researchers have identified plausible biological pathways through which CBD might exert beneficial effects, but no human clinical trials are cited that demonstrate CBD actually works for any of these conditions in patients. Similarly, readers may assume that because CBD is FDA-approved for epilepsy, its safety and efficacy for oral applications are established. In reality, approval for one indication says nothing about efficacy in another, and the oral cavity presents a unique microbiological and immunological environment that cannot be inferred from systemic studies. The routes of administration discussed in the review are proposed research directions, not clinically validated dental delivery systems.

This review contributes a useful mechanistic map of cannabinoid receptor systems in oral tissues and identifies five disease categories where CBD research could be pursued. It does not establish that CBD is effective, safe, or ready for clinical use in any oral disease. For clinicians, the review is best understood as a research roadmap, not a treatment rationale, and patients asking about CBD for dental conditions should be counseled that the scientific story, while biologically interesting, remains in its earliest chapters.

Can CBD cure gum disease or periodontal disease?

No. While laboratory studies suggest that CBD has anti-inflammatory and antibacterial properties that could theoretically benefit gum health, there are no clinical trials demonstrating that CBD treats or cures periodontal disease in humans. Standard dental care, including professional cleanings and proper oral hygiene, remains the evidence-based approach.

Is it safe to use CBD products in my mouth?

CBD is generally considered to have a favorable safety profile based on studies in other conditions, but its long-term safety when applied directly to oral tissues has not been rigorously studied. CBD can also interact with certain medications through liver enzyme inhibition, so patients taking other drugs should discuss CBD use with their healthcare provider before starting.

Does this review mean CBD will soon be prescribed by dentists?

Not in the near term. This review identifies biological reasons to study CBD for dental conditions, but clinical trials in actual patients are needed before any dental prescribing could be considered. The path from preclinical promise to clinical approval typically takes many years, as the history of CBD in epilepsy treatment illustrates.

Should I stop my current dental treatment and try CBD instead?

Absolutely not. There is no evidence that CBD can replace any established dental treatment. If you are interested in trying CBD as a supplement alongside your regular dental care, discuss this with both your dentist and your physician to ensure it does not interfere with your current medications or treatment plan.

What would it take for CBD to become an accepted treatment for oral diseases?

Researchers would need to conduct well-designed randomized controlled trials comparing CBD to placebo or standard care in patients with specific oral diseases, measuring clinically meaningful outcomes such as reduced inflammation, pain relief, or tumor response. These trials would need to establish not only efficacy but also appropriate dosing, delivery methods, and safety profiles specific to the oral cavity.

Have thoughts on this? Share it: